The Primary
Care Companionfor CNS Disorders

Suicide

Letter to the Editor October 15, 2008

Low Cholesterol, Delinquency, and Suicidality

Luca Mascitelli, M.D.; Francesca Pezzetta, M.D.; Mark R. Goldstein, M.D.

Prim Care Companion J Clin Psychiatry 2008;10(5):413-414

Article Abstract

Letter to the Editor

Low Cholesterol, Delinquincy, and Suicidality

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 26 • 2024 • Number 6

Read the Current Issue

Narrative Review

Dextromethorphan-Quinidine for Agitation in Dementia

Original Research

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Original Research

Intervention to Enhance Mental Health Competency

Original Research

Evolution of Treatment Modalities for PTSD

Rounds in the General Hospital

Etiology, Prevention, and Management of TD

Rounds in the General Hospital

Comorbid Bipolar Disorder and PTSD

View current Issue

Letter to the Editor

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.

Bénédicte Nobile, Philippe Courtet

Letter to the Editor

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.

Laura Palagini, Pierre A. Geoffroy, Jean Arthur Micoulaud-Franchi, et al

Letter to the Editor

Possible Suicidal Risk With Daridorexant

December 7, 2022

Instructions for use of the new anti-insomnia medication daridorexant mention cautious use in patients with history of suicidal behavior. This letter explores the factors that underlie this recommendation for...

Bénédicte Nobile, Emilie Olié, Philippe Courtet

Low Cholesterol, Delinquency, and Suicidality

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

ELSEWHERE:

FOLLOW US:

Low Cholesterol, Delinquency, and Suicidality

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

Related Articles

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

Possible Suicidal Risk With Daridorexant

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles